Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Cited by (1,000)

Items 801–900 of 1,000

1. The Role of Axl Receptor Tyrosine Kinase in Tumor Cell Plasticity and Therapy Resistance
   Kjersti T. Davidsen, Gry Sandvik Haaland, Maria K. Lie, James B. Lorens, Agnete S. T. Engelsen · 2017 · Springer eBooks
2. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis
   Xiaoli Wu · 2017 · Gene
3. The hippo pathway provides novel insights into lung cancer and mesothelioma treatment
   Xiaolan Liu, Rui Min Zuo, Wen‐Bin Ou · 2018 · Journal of Cancer Research and Clinical Oncology
4. Oxidized Vitamin C (DHA) Overcomes Resistance to EGFR-targeted Therapy of Lung Cancer through Disturbing Energy Homeostasis
   Mingtong Ye, Nengzhi Pang, Ting Wan, Yuanling Huang, Tianyi Wei, Xuye Jiang, Yujia Zhou, Yu‐Feng Huang, Hainan Yang, Zhenfeng Zhang et al. · 2019 · Journal of Cancer
5. Efficient Arylation of 2,7-Naphthyridin-1(2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor
   Mingshu Wang, Hong-Chuang Xu, Yi Gong, Ren‐Yu Qu, Linsheng Zhuo, Wei Huang · 2020 · ACS Combinatorial Science
6. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice
   Cheng-Ta Chung, Kai‐Chia Yeh, Chia‐Huei Lee, Yunyu Chen, Pai-Jiun Ho, Kai-Yen Chang, Chieh‐Hsin Chen, Yiu‐Kay Lai, Chiung‐Tong Chen · 2020 · Pharmacological Research
7. Integrated Proteomics-Based Physical and Functional Mapping of AXL Kinase Signaling Pathways and Inhibitors Define Its Role in Cell Migration
   Anurima Majumder, Sina Hosseinian, Mia Stroud, Emma Adhikari, James Joseph Saller, Matthew A. Smith, Guolin Zhang, Shruti Agarwal, Marc Creixell, Benjamin S. Meyer et al. · 2022 · Molecular Cancer Research
8. Axl-Targeted Cancer Imaging with Humanized Antibody h173
   Dan Li, Shuanglong Liu, Ren Liu, Ryan Jin-hyung Park, Haiyang Yu, Valery G. Krasnoperov, Parkash S. Gill, Zibo Li, Hong Shan, Peter S. Conti · 2014 · Molecular Imaging and Biology
9. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer
   Nobuaki Ochi, Hideko Isozaki, Masami Takeyama, Jack W. Singer, Hiromichi Yamane, Yoshihiro Honda, Katsuyuki Kiura, Nagio Takigawa · 2016 · Experimental Cell Research
10. Resistance to Therapy
    Gabriel A. Rivera, Heather A. Wakelee · 2016 · Cancer treatment and research
11. Adaptive mechanisms of resistance to anti-neoplastic agents
    Bibiana I. Ferreira, Maria K. Lie, Agnete S. T. Engelsen, Susana Machado, Wolfgang Link, James B. Lorens · 2016 · MedChemComm
12. Micropillar‐based culture platform induces epithelial–mesenchymal transition in the alveolar epithelial cell line
    Xiaoli Xu, Lunkun Ma, Yanjiao Wu, Liling Tang · 2018 · Journal of Biomedical Materials Research Part A
13. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR‐mutated non–small cell lung cancer
    Yoshikane Nonagase, Masayuki Takeda, Koichi Azuma, Hidetoshi Hayashi, Koji Haratani, Kaoru Tanaka, Kimio Yonesaka, Hidenobu Ishii, Tomoaki Hoshino, Kazuhiko Nakagawa · 2019 · Thoracic Cancer
14. Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
    Hao Huang, Alexander Gont, Lynn Kee, Ruben Dries, Kathrin Pfeifer, Bandana Sharma, David N. Debruyne, Matt L. Harlow, Satyaki Sengupta, Jikui Guan et al. · 2021 · Cell Reports
15. Brain Metastases from Non-Small Cell Lung Cancer
    Mohammad Houman Fekrazad, Omid Sanaei, Julie E. Bauman, Dennie V. Jones · 2014 · Elsevier eBooks
16. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells
    JungMin Choi, Ji-Young Jang, Yu-Ra Choi, Hye Ryun Kim, Byoung Chul Cho, Han‐Woong Lee · 2015 · Lung Cancer
17. Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs
    Monique B. Nilsson, Xiuning Le, Alissa Poteete, Xiaoxing Yu, Junqin He, Qian Huang, Yuji Shibata, Ximeng Liu, Cesar Moran, Ash A. Alizadeh et al. · 2026 · Journal of Thoracic Oncology
18. HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer
    Tianyao Lei, Jiali Huang, Fei Xie, Jingyao Gu, Zhixiang Cheng, Zhaoxia Wang · 2022 · Acta Biochimica et Biophysica Sinica
19. PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
    Xia Ding, Zhou Zhu, John D. Lapek, Elizabeth A. McMillan, Alexander Zhang, Chi‐Yeh Chung, Sara J. Dubbury, Jennifer Lapira, Sarah J. Firdaus, Xiaolin Kang et al. · 2022 · Scientific Reports
20. Antitumor effects of erlotinib in combination with berberine in A431 cells
    Xiangdan Cuan, Xingying Yang, Weiwei Zhu, Yue Zhao, Rui Luo, Yanping Huang, Xuanjun Wang, Jun Sheng · 2023 · BMC Pharmacology and Toxicology
21. Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance
    Selene K. Roberts, Ioannis Galgadas, David T. Clarke, Laura C. Zanetti-Domingues, Francesco Luigi Gervasio, Marisa L. Martin-Fernandez · 2025 · Drug Discovery Today
22. Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women
    Lavina Ahmed, Hawa Nalwoga, Jarle B. Arnes, Henry Wabinga, David Micklem, Lars A. Akslen · 2015 · Apmis
23. Simultaneous Inhibition of EGFR and HER2 via Afatinib Augments the Radiosensitivity of Nasopharyngeal Carcinoma Cells
    Fangling Huang, Xujun Liang, Xiaoli Min, Ye Zhang, Bing Wang, Zhengrong Peng, Fang Peng, Maoyu Li, Lin Chen, Yongheng Chen · 2019 · Journal of Cancer
24. TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
    Jeong‐Yun Choi, Haeseung Lee, Eun‐Ji Kwon, Hyeon‐Joon Kong, Ok‐Seon Kwon, Hyuk‐Jin Cha · 2020 · Molecular Oncology
25. Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity
    Wongeun Lee, Dong Kwon Kim, Chun‐Bong Synn, Hee Kyu Lee, Sung Ho Park, Dong-Sik Jung, Yewon Choi, Jae Hwan Kim, Youngseon Byeon, Young Seob Kim et al. · 2022 · Frontiers in Oncology
26. The epigenome and the many facets of cancer drug tolerance
    Paul C. Moore, Kurt W. Henderson, Marie Classon · 2023 · Advances in cancer research
27. miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance
    Biagio Ricciuti · 2015 · ecancermedicalscience
28. Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPV-negative penile carcinogenesis
    Jieping Chen, Kai Yao, Zaishang Li, Chuangzhong Deng, Liangjiao Wang, Xingsu Yu, Peili Liang, Qiankun Xie, Peng Chen, Zike Qin et al. · 2016 · Oncotarget
29. Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer
    Xueming Ying, Jun Chen, Xueming Huang, Peng Huang, Shao-Cong Yan · 2017 · Experimental and Therapeutic Medicine
30. Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms
    Claudia Proto, Giuseppe Lo Russo, Giulia Corrao, Monica Ganzinelli, Francesco Facchinetti, Roberta Minari, Marcello Tiseo, Marina Chiara Garassino · 2017 · Tumori Journal
31. Targeting PKCι-PAK1 in EGFR-mutation positive non-small cell lung cancer
    Masaoki Ito, Carles Codony, Niki Karachaliou, Rafael Rosell · 2019 · Translational Lung Cancer Research
32. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma
    Antonino Belfiore, Adele Busico, Fabio Bozzi, Silvia Brich, Elena Dallera, Elena Conca, Iolanda Capone, Annunziata Gloghini, Chiara Costanza Volpi, Antonello Domenico Cabras et al. · 2019 · International Journal of Molecular Sciences
33. Overcoming the Intrinsic Gefitinib-resistance via Downregulation of AXL in Non-small Cell Lung Cancer
    Inae Jeong, Jayoung Song, Song Yi Bae, Sang Kook Lee · 2019 · Journal of Cancer Prevention
34. Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers—Applications and Limitations
    Shuta Ohara, Kenichi Suda, Tetsuya Mitsudomi · 2021 · Cells
35. Structural Elucidation of the DFG-Asp in and DFG-Asp out States of TAM Kinases and Insight into the Selectivity of Their Inhibitors
    Abdellah Messoussi, Lucile Peyronnet, Clémence Feneyrolles, Gwénaël Chevé, Khalid Bougrin, Abdelaziz Yasri · 2014 · Molecules
36. Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals
    Helen He Zhu, Xiaolin Luo, Kaiqing Zhang, Jian Guo Cui, Huifang Zhao, Zhongzhong Ji, Zhicheng Zhou, Jufang Yao, Li‐Fan Zeng, Kaihong Ji et al. · 2015 · Proceedings of the National Academy of Sciences
37. The Role of Proteomics and Phosphoproteomics in the Discovery of Therapeutic Targets and Biomarkers in Acquired EGFR-TKI-Resistant Non-Small Cell Lung Cancer
    Sutpirat Moonmuang, Apichat Tantraworasin, Santhasiri Orrapin, Sasimol Udomruk, Busayamas Chewaskulyong, Dumnoensun Pruksakorn, Parunya Chaiyawat · 2023 · International Journal of Molecular Sciences
38. AXL receptor tyrosine kinase inhibition improves the anti-tumor effects of CD8+ T cells by inducing CD103+ dendritic cell-mediated T cell priming
    Kyungtaek Im, Yun Jung Choi, Dong Ha Kim, Dasom Kim, Kyosun Ban, Wonjun Ji, In‐Jeoung Baek, Chang‐Min Choi, Jae Cheol Lee, Jin Kyung Rho · 2023 · Biochemical and Biophysical Research Communications
39. AXL Tyrosine Kinases: A Growing Isoform Family That Promotes Cancer Pathogenesis
    May Eriksen Gjerstad, Pia Aehnlich, Pascal Gélébart, Emmet McCormack · 2025 · Cancer Research
40. Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives
    Raffaele Costanzo, Agnese Montanino, Massimo Di Maïo, Maria Carmela Piccirillo, Claudia Sandomenico, Pasqualina Giordano, Gennaro Daniele, Renato Franco, Francesco Perrone, Gaetano Rocco et al. · 2013 · Expert Review of Anticancer Therapy
41. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation
    Kenichi Suda, Hiroshi Mizuuchi, Isao Murakami, Hidetaka Uramoto, Fumihiro Tanaka, Katsuaki Sato, Toshiki Takemoto, Takuya Iwasaki, Yoshitaka Sekido, Yasushi Yatabe et al. · 2014 · Lung Cancer
42. Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
    J.L. González-Larriba, Martín Lázaro-Quintela, Manuel Cobo, Manuel Dómine, Margarita Majem, Rosario García‐Campelo · 2017 · Translational Lung Cancer Research
43. ZNF224 is a transcriptional repressor of AXL in chronic myeloid leukemia cells
    Gaetano Sodaro, Giancarlo Blasio, Federica Fiorentino, Patrick Auberger, Paola Costanzo, Elena Cesaro · 2018 · Biochimie
44. Characterising acquired resistance to erlotinib in non-small cell lung cancer patients
    Niki Karachaliou, Jordi Codony‐Servat, Jillian Wilhelmina Paulina Bracht, Masaoki Ito, Martyna Filipska, Carlos Pedraz‐Valdunciel, Imane CHAIB-OUKADOUR, Jordi Bertrán-Alamillo, Andrés Felipe Cardona, Miguel Ángel Molina‐Vila et al. · 2019 · Expert Review of Respiratory Medicine
45. Chemotherapy confers a conserved secondary tolerance to EGFR inhibition via AXL-mediated signaling bypass
    Mark Borris D. Aldonza, Roben Delos Reyes, Young Seo Kim, Jayoung Ku, Ana Melisa Barsallo, Ji-Young Hong, Sang Kook Lee, Han Suk Ryu, YongKeun Park, Je‐Yoel Cho et al. · 2021 · Scientific Reports
46. Discovery of a potent and selective Axl inhibitor in preclinical model
    Satoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, Hiroshi Azuma, Satoshi Nagao, Norio Murai, Kyoko Nishibata, Sayo Fukushima, Kenji Ichikawa, Takayuki Nakagawa et al. · 2021 · Bioorganic & Medicinal Chemistry
47. EGFR and c-Met Inhibitors are Effective in Reducing Tumorigenicity in Cancer
    Amanda Stone · 2014 · Journal of Carcinogenesis & Mutagenesis
48. Protein Binders Specific for Immunoglobulin G from Different Species for Immunoassays and Multiplex Imaging
    Sukyo Jeong, Woosung Heu, Jong‐Won Kim, Hak‐Sung Kim · 2016 · Analytical Chemistry
49. Evaluation of 99mTc-HYNIC-MPG as a novel SPECT radiotracer to detect EGFR-activating mutations in NSCLC
    Zunyu Xiao, Yan Song, Wang Kai, Xilin Sun, Baozhong Shen · 2017 · Oncotarget
50. The impact of competition between cancer cells and healthy cells on optimal drug delivery
    Heyrim Cho, Doron Levy · 2020 · Mathematical Modelling of Natural Phenomena
51. Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection
    Tiong Sun Chia, Kwong‐Fai Wong, John Moon Luk · 2019 · Hepatoma Research
52. Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling
    Oh, Hwanhee, Hwang, Inah, Jang, Ja-Young, Wu, Lingxiang, Cao, Dongqing, Yao, Jun, Ying, Haoqiang, Li, Jian Yi, Yao, Yu, Hu, Baoli et al. · 2021 · Cancer Research
53. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
    Dora Barbosa Rabago, Collin Michael Blakely, Franziska Haderk, Trever Grant Bivona · 2021 · Journal of Visualized Experiments
54. TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer
    Vinod Kumar, Zachary Alan Yochum, Princey Devadassan, Eric H.‐B. Huang, Ethan Miller, Roja Baruwal, Purva H. Rumde, Autumn Gaither‐Davis, Laura P. Stabile, Timothy Francis Burns · 2024 · Oncogene
55. HGF/c‐Met Promotes Breast Cancer Tamoxifen Resistance Through the EZH2/HOTAIR‐miR‐141/200a Feedback Signaling Pathway
    Lai, Xiaofeng, Zhang, Yuan, Li, Mengyang, Yu, Shentong, Wang, Shuiliang, Zhang, Shenghang, Niu, Huimin, Chen, Li, Lan, Xiaopeng, Zhang, Jian et al. · 2025 · Molecular Carcinogenesis
56. Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
    Haocheng Wang, Xue Ling Yang, Yang Sun, Yanan Li, Ya Dong, Dongfeng Shan, Zhuang Yu · 2020 · Translational Cancer Research
57. The Role of Epidermal Growth Factor Receptor Signaling Pathway during Bovine Herpesvirus 1 Productive Infection in Cell Culture
    Wencai Qiu, Long Chang, Yong‐Ming He, Liqian Zhu · 2020 · Viruses
58. Anti‑Axl monoclonal antibodies attenuate the migration of MDA‑MB‑231 breast cancer cells
    Hong Chang, Ran An, Xinying Li, Xiaoling Lang, Jiannan Feng, Ming Lv · 2021 · Oncology Letters
59. Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses
    Masahisa Jinushi · 2014 · Cancer and Metastasis Reviews
60. The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology
    Marialuigina Fruscella, Antonio Ponzetto, Annalisa Crema, Guido Carloni · 2016 · Journal of Nanotechnology
61. Gas6-Axl signaling in presence of Sunitinib is enhanced, diversified and sustained in renal tumor cells, resulting in tumor-progressive advantages
    Anna Gustafsson, Helena K. M. Fritz, Björn Dahlbäck · 2017 · Experimental Cell Research
62. BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
    Niki Karachaliou, Oscar G. Arrieta, Ana A. Giménez-Capitán, Erika Aldeguer, Ana Drozdowskyj, Imane CHAIB-OUKADOUR, Noemı́ Reguart, Rosario García‐Campelo, Jinghua Chen, Miguel Ángel Molina‐Vila et al. · 2020 · JTO Clinical and Research Reports
63. Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
    Yun Jung Choi, Gun Min Park, Jin Kyung Rho, Sun Ye Kim, Gwang Sup So, Hyeong Ryul Kim, Chang‐Min Choi, Jae Cheol Lee · 2013 · PLoS ONE
64. Label-Free SERS Sensors for Real-Time Monitoring of Tyrosine Phosphorylation
    Ailsa Geddis, Lorena Mendive‐Tapia, Audreylia Sujantho, Erica Liu, Sarah McAughtrie, Richard J. A. Goodwin, Marc Vendrell, Colin J. Campbell · 2024 · Analytical Chemistry
65. Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets
    Nathan M. Kendsersky, Michal Odrobina, Nathaniel W. Mabe, Alvin Farrel, Liron D. Grossmann, Matthew Tsang, David Groff, Adam J. Wolpaw, Alaa Narch, Francesca Zammarchi et al. · 2025 · Neuro-Oncology
66. Cytokine and epigenetic regulation of CEACAM6 mediates EGFR-driven signaling and drug response in lung adenocarcinoma
    Ming‐Yi Zheng, Yen‐Ting Lin, Yen‐Shou Kuo, Yen‐Ju Lin, Ming-Han Kuo, Tsai-Wang Huang, Yi‐Shing Shieh, Yenlin Huang, Yu‐Ting Chou · 2025 · npj Precision Oncology
67. Phytochemical profiling and anticancer potential of pistachio wastes against MCF-7 breast cancer cells: a metabolic and apoptotic pathway analysis
    Levent Gülüm, Emrah Güler, Çağla Başak Zırhlı, Ayşe Büşranur Çelik, Yusuf Tutar · 2025 · BMC Complementary Medicine and Therapies
68. EMT-ciliary signaling in quasi-mesenchymal-stem-like cells drives therapeutic resistance and is a druggable vulnerability in triple-negative breast cancer
    Camille E. Tessier, Jennifer Derrien, Aurore M. M. Dupuy, Thomas Pelé, Martin Moquet, Julie Roul, Elise Douillard, Camille El Harrif, Xavier Pinson, Matthieu Le Gallo et al. · 2025 · EMBO Molecular Medicine
69. GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma
    Xiaoshen Zhang, Yaokai Wen, Fengying Wu, Yu Jiang, Yuechun Lin, Lei Wang, Fei Zhou, Yue Shen, Zhen Min, Wei Li et al. · 2025 · Journal of Thoracic Oncology
70. Synthesis and Biological Evaluation of Novel 4,5,6,7-Tetrahydrobenzo[D]-Thiazol-2- Yl Derivatives Derived from Dimedone with Anti-Tumor, C-Met, Tyrosine Kinase and Pim-1 Inhibitions
    Rafat M. Mohareb, Amr Salah Abouzied, Nermeen Saeed Abbas · 2019 · Anti-Cancer Agents in Medicinal Chemistry
71. Limb expression 1‐like protein promotes epithelial–mesenchymal transition and epidermal growth factor receptor‐tyrosine kinase inhibitor resistance via nucleolin‐mediated ribosomal RNA synthesis in non‐small cell lung cancer
    Minglei Li, Jiaxi Zhang, Xue Meng, Bei Liu, Shelly M. Xie, Fang Liu, Demin Yao, Jingguo Zhang, Haitao Shen, Lingxiao Xing · 2022 · Cancer Science
72. The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma
    Sebastiaan M. Schieven, Joleen J.H. Traets, Alex v. Vliet, Martijn v. Baalen, Ji‐Ying Song, Marcos Da Silva Guimaraes, Thomas Kuilman, Daniel S. Peeper · 2023 · Molecular Cancer Research
73. Moving Towards Molecular-Guided Treatments: Erlotinib and Clinical Outcomes in Non-Small-Cell Lung Cancer Patients
    Mariacarmela Santarpía, Tommaso Martino De Pas, Giuseppe Altavilla, Lorenzo Spaggiari, Rafael Rosell · 2013 · Future Oncology
74. Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
    Nayoung Kim, Ahye Cho, Hideo Watanabe, Yoon‐La Choi, Meraj Aziz, Michelle Kassner, Je‐Gun Joung, Angela Kyung-Joo Park, Joshua M. Francis, Joon Seol Bae et al. · 2016 · Oncotarget
75. The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy
    Janaki Neela Sharma, Elaine Shum, Vincent Chau, Daniel Paucar, Haiying Cheng, Balázs Halmos · 2016 · Respiration
76. Oncogenic functions of ZEB1 in pediatric solid cancers: interplays with microRNAs and long noncoding RNAs
    Lívia Fratini, Mariane da Cunha Jaeger, Caroline Brunetto de Farias, Andre Tesainer Brunetto, Algemir Lunardi Brunetto, Lisa Shaw, Rafael Roesler · 2021 · Molecular and Cellular Biochemistry
77. Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance
    Zachary Alan Yochum, Mark A. Socinski, Timothy Francis Burns · 2016 · Journal of Thoracic Disease
78. Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
    James Chih‐Hsin Yang, Wu‐Chou Su, Chao‐Hua Chiu, Her‐Shyong Shiah, Kang‐Yun Lee, Te‐Chun Hsia, Makiko Uno, Nigel Crawford, Hiroshi Terakawa, Wen‐Chi Chen et al. · 2023 · Investigational New Drugs
79. MET/HGF targeted drugs as potential therapeutic strategies in non-small cell lung cancer
    Cristina Pérez-Ramírez, Marisa Cañadas‐Garre, Miguel Ángel Molina‐Vila, María José Faus-Dáder, Miguel Ángel Calleja‐Hernández · 2015 · Pharmacological Research
80. Quantitative Tyrosine Phosphoproteome Profiling of AXL Receptor Tyrosine Kinase Signaling Network
    Xinyan Wu, Li Wang, Nicole A Pearson, Santosh Renuse, Ran Cheng, Ye Liang, Dong‐Gi Mun, Anil Kumar Madugundu, Yaoyu Xu, Parkash S. Gill et al. · 2021 · Cancers
81. Epithelial–Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress
    Mingwei Liang, Jennifer W. Li, Huacheng Luo, Sarah Lulu, Ozlem Calbay, Anitha Kota Shenoy, Ming Tan, Brian Keith Law, Shuang Huang, Tsan Sam Xiao et al. · 2022 · Cells
82. Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
    Nataliya A. Pidkovka, Abbes Belkhiri · 2023 · Frontiers in Oncology
83. PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up
    Claire Lailler, Audrey Didelot, Simon Garinet, Hugo Berthou, Marine Sroussi, Aurélien de Reyniès, Shoukat Dedhar, Severine Martin‐Lannerée, Elizabeth Fabre, Françoise Le Pimpec‐Barthes et al. · 2024 · Oncogene
84. New twists in the AXL(e) of tumor progression
    Balázs Halmos, Eric B. Haura · 2016 · Science Signaling
85. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer
    Carlo Genova, Erika Rijavec, Federica Biello, Giovanni Rossi, Giulia Barletta, Maria Giovanna Dal Bello, Irene Vanni, Simona Coco, Angela Alama, Francesco Grossi · 2016 · Expert Opinion on Pharmacotherapy
86. Eukaryotic translation initiation factor 3 subunit C is associated with acquired resistance to erlotinib in non-small cell lung cancer
    Takuya Shintani, Kazuma Higashisaka, Makiko Maeda, Masaya Hamada, Ryosuke Tsuji, Koudai Kurihara, Yuri Kashiwagi, Atsuhiro Sato, Masanori Obana, Ayaha Yamamoto et al. · 2018 · Oncotarget
87. Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration
    Yanting Duan, Bo Hu, Chunxia Qiao, Longlong Luo, Xinying Li, Jing Wang, Hao Liu, Tingting Zhou, Beifen Shen, Ming Lv et al. · 2019 · Oncology Letters
88. Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
    Ana I. Velázquez, Caroline Elizabeth McCoach · 2020 · Journal of Thoracic Disease
89. A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer
    Chih-Ming Su, Ting-Yu Chang, Hui‐Ping Hsu, Hui‐Huang Lai, Jie‐Ning Li, Yu-Jhen Lyu, Kuang-Tai Kuo, Ming‐Te Huang, Jen-Liang Su, Pai‐Sheng Chen · 2016 · Oncotarget
90. Synthesis of Tetrahydrobenzo[b]thiophene-3-carbohydrazide Derivatives as Potential Anti-cancer Agents and Pim-1 Kinase Inhibitors
    Rafat M. Mohareb, Wagnat W. Wardakhan, Nermeen Saeed Abbas · 2019 · Anti-Cancer Agents in Medicinal Chemistry
91. Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors
    Satoshi Inoue, Yoshinobu Yamane, Shuntaro Tsukamoto, Norio Murai, Hiroshi Azuma, Satoshi Nagao, Kyoko Nishibata, Sayo Fukushima, Kenji Ichikawa, Takayuki Nakagawa et al. · 2021 · Bioorganic & Medicinal Chemistry Letters
92. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
    Ana Chocarro‐Calvo, Miguel Jociles-Ortega, José Manuel García-Martínez, Pakavarin Louphrasitthiphol, Sofia Carvalho-Marques, Yurena Vivas, Ana Ramírez-Sánchez, Jagat Singh Chauhan, Carmen Fiuza, Manuel Durán et al. · 2025 · Genes & Development
93. Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer
    Tackhoon Kim, Byung-Sun Park, Soobeen Heo, Heeju Jeon, Jaeyeal Kim, Donghwa Kim, Sang Kook Lee, So‐Youn Jung, Sun‐Young Kong, Timothy K. Lu · 2024 · eLife
94. Phase 1 study of DS‐1205c combined with gefitinib for EGFR mutation‐positive non‐small cell lung cancer
    Kōichi Goto, Yoshimasa Shiraishi, Haruyasu Murakami, Hidehito Horinouchi, Ryo Toyozawa, Masayuki Takeda, Makiko Uno, Nigel Crawford, Joseph McGill, Takeshi Jimbo et al. · 2023 · Cancer Medicine
95. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable
    Tamara Codilupi, Jakub Szybinski, Stefanie Arunasalam, Sarah Jungius, Andrew Jeffrey Dunbar, Simona Stivala, Šime Brkić, Camille Albrecht, Lenka Vokálová, Julie L. Yang et al. · 2023 · Clinical Cancer Research
96. Emerging Techniques in Spatial Multiomics: Fundamental Principles and Applications to Dermatology
    Bojing Blair Jia, Bryan K. Sun, Ernest Y. Lee, Bing Ren · 2024 · Journal of Investigative Dermatology
97. Repurposing Artemisinin-Based Drugs from Antimalarial to Pan-Therapeutic: Pharmacological Promise and Therapeutic Challenges
    Di Wu, Hong Zeng, Jiachen Tan, Qianqian Xu, Faheem Ahmed Khan, Nuruliarizki Shinta Pandupuspitasari, Shengqiang Yang, Chunjie Huang · 2025 · Drug Design Development and Therapy
98. The miR-200 Family in Non-Small-Cell Lung Cancer: Molecular Mechanisms, Clinical Applications, and Therapeutic Implications
    Nobuaki Kobayashi, Yukihito Kajita, Fangfei Yang, Nobuhiko Fukuda, Kohei Somekawa, Ayami Kaneko, Seigo Katakura · 2025 · Genes
99. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
    Lívia Bassani Lins de Miranda, Keli Lima, Juan Luiz Coelho‐Silva, Fabı́ola Traina, Susumu S. Kobayashi, João Agostinho Machado‐Neto · 2022 · Scientific Reports
100. AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers
     Xiaobai Sun, Hong Chen, Shuling You, Zhikang Tian, Zhaoyu Wang, Fulin Liu, Wenyi Hu, Hao Zhang, Guoan Zhang, Hongli Zhao et al. · 2023 · Molecular and Clinical Oncology